These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35990741)

  • 1. Protocol for stratification of triple-negative breast cancer patients using
    Imoto H; Yamashiro S; Murakami K; Okada M
    STAR Protoc; 2022 Sep; 3(3):101619. PubMed ID: 35990741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
    Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
    Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer.
    Apaya MK; Shiau JY; Liao GS; Liang YJ; Chen CW; Yang HC; Chu CH; Yu JC; Shyur LF
    J Exp Clin Cancer Res; 2019 May; 38(1):187. PubMed ID: 31072371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A text-based computational framework for patient -specific modeling for classification of cancers.
    Imoto H; Yamashiro S; Okada M
    iScience; 2022 Mar; 25(3):103944. PubMed ID: 35535207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systems Medicine Design for Triple-Negative Breast Cancer and Non-Triple-Negative Breast Cancer Based on Systems Identification and Carcinogenic Mechanisms.
    Yeh SJ; Hsu BJ; Chen BS
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pipeline of integrating transcriptome and interactome to elucidate central nodes in host-pathogens interactions.
    Kumar N; Mishra B; Mukhtar MS
    STAR Protoc; 2022 Sep; 3(3):101608. PubMed ID: 35990739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic regulation of triple negative breast cancer (TNBC) by TGF-β signaling.
    Vishnubalaji R; Alajez NM
    Sci Rep; 2021 Jul; 11(1):15410. PubMed ID: 34326372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances of transcriptomics and proteomics in triple-negative breast cancer prognosis assessment.
    Li Y; Kong X; Wang Z; Xuan L
    J Cell Mol Med; 2022 Mar; 26(5):1351-1362. PubMed ID: 35150062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
    Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
    Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of key genes as potential biomarkers for triple‑negative breast cancer using integrating genomics analysis.
    Zhong G; Lou W; Shen Q; Yu K; Zheng Y
    Mol Med Rep; 2020 Feb; 21(2):557-566. PubMed ID: 31974598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. hCoCena: A toolbox for network-based co-expression analysis and horizontal integration of transcriptomic datasets.
    Holsten L; Dahm K; Oestreich M; Becker M; Ulas T
    STAR Protoc; 2024 Mar; 5(1):102922. PubMed ID: 38427570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inferring disease progression and gene regulatory networks from clinical transcriptomic data using PROB_R.
    Dong Z; Sun X
    STAR Protoc; 2022 Sep; 3(3):101467. PubMed ID: 35733604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC).
    Narrandes S; Huang S; Murphy L; Xu W
    BMC Cancer; 2018 Jan; 18(1):22. PubMed ID: 29301506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analyzing single cell transcriptome data from severe COVID-19 patients.
    Nassir N; Tambi R; Bankapur A; Karuvantevida N; Khansaheb HH; Zehra B; Begum G; Hameid RA; Ahmed A; Deesi Z; Alkhajeh A; Uddin KMF; Akter H; Safizadeh Shabestari SA; Gaudet M; Hachim MY; Alsheikh-Ali A; Berdiev BK; Al Heialy S; Uddin M
    STAR Protoc; 2022 Jun; 3(2):101379. PubMed ID: 35582459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
    Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
    Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protocol for using Ciclops to build models trained on cross-platform transcriptome data for clinical outcome prediction.
    Chou E; Zhang H; Guan Y
    STAR Protoc; 2022 Sep; 3(3):101583. PubMed ID: 35880126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer.
    Shin SY; Müller AK; Verma N; Lev S; Nguyen LK
    PLoS Comput Biol; 2018 Jun; 14(6):e1006192. PubMed ID: 29920512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.
    Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
    Front Immunol; 2021; 12():749459. PubMed ID: 34603338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative analysis of somatic mutations and transcriptomic data to functionally stratify breast cancer patients.
    Zhang J; Abrams Z; Parvin JD; Huang K
    BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):513. PubMed ID: 27556157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.
    De Santis F; Romero-Cordoba SL; Castagnoli L; Volpari T; Faraci S; Fucà G; Tagliabue E; De Braud F; Pupa SM; Di Nicola M
    Cell Oncol (Dordr); 2022 Apr; 45(2):257-274. PubMed ID: 35357654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.